GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (STU:NJT) » Definitions » Total Liabilities

Regenetp (STU:NJT) Total Liabilities : €5.26 Mil (As of Mar. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Regenetp Total Liabilities?

Regenetp's Total Liabilities for the quarter that ended in Mar. 2023 was €5.26 Mil.

Regenetp's quarterly Total Liabilities increased from Sep. 2022 (€5.25 Mil) to Dec. 2022 (€5.88 Mil) but then declined from Dec. 2022 (€5.88 Mil) to Mar. 2023 (€5.26 Mil).

Regenetp's annual Total Liabilities declined from Dec. 2020 (€14.94 Mil) to Dec. 2021 (€10.56 Mil) and declined from Dec. 2021 (€10.56 Mil) to Dec. 2022 (€5.88 Mil).


Regenetp Total Liabilities Historical Data

The historical data trend for Regenetp's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Total Liabilities Chart

Regenetp Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.38 13.22 14.94 10.56 5.88

Regenetp Quarterly Data
Apr18 Jul18 Oct18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.12 7.55 5.25 5.88 5.26

Regenetp Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Regenetp's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.951+(2.523+1.406
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=5.88

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=21.568-15.687
=5.88

Regenetp's Total Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.029+(2.33+0.898
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=5.26

Total Liabilities=Total Assets (Q: Mar. 2023 )-Total Equity (Q: Mar. 2023 )
=16.858-11.601
=5.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenetp Total Liabilities Related Terms

Thank you for viewing the detailed overview of Regenetp's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenetp (STU:NJT) Business Description

Traded in Other Exchanges
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Regenetp (STU:NJT) Headlines

No Headlines